Celentyx’s unique Immuno-Profiling™ platform technology allows rapid analysis of drug or biopharmaceutical action on human immune cells (normal resting or activated, or pathological).
In addition to investigating drug action at the level of peripheral blood mononuclear cells (PBMC), Celentyx can investigate the precise impact of a drug on extremely small, yet critical immune cell subpopulations.
Schematic illustrating some of the critical immune cell subsets within PBMC which Celentyx are able to investigate:
In addition to 'normal' immune cells, Celentyx is able to study drug actions on cells from various immune pathologies, including several haematological malignancies.
Celentyx allows access to it's powerful Immuno-Profiling™ platform through it's Immuno-Profiling™ services.